Carlyle Group in Talks to Acquire Baxter’s Vantive for Over $4 Billion

Private equity firm Carlyle Group is currently in exclusive negotiations to acquire Baxter International’s kidney care spinoff, Vantive, for more than $4 billion, including debt. This potential acquisition marks a significant move in the healthcare sector.

Following the news, shares of Baxter International, based in Deerfield, Illinois, surged by over 4%, reflecting investor optimism about the potential deal.

Negotiation Details:

Negotiations between Carlyle Group and Baxter began in late June, and according to a source familiar with the matter, a formal agreement could be announced in the coming weeks, pending finalization.

Baxter’s decision to explore the sale of Vantive comes over a year after announcing plans to separate the kidney care unit. Supply-chain challenges and subdued demand in the dialysis market prompted this move.

Future Outlook:

Baxter had previously indicated its intention to complete the separation of the kidney care unit in the latter half of the year, underscoring its strategic restructuring efforts.

While Baxter declined to comment on the ongoing negotiations, Carlyle Group has not yet responded to media inquiries seeking confirmation of the deal.